Annual report pursuant to Section 13 and 15(d)

Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)

v3.22.0.1
Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)
 1 Months Ended 12 Months Ended
May 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
Faculty
Dec. 31, 2020
USD ($)
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Research and development expense   $ 32,494,000 $ 21,376,000
License Agreement      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Obligation to be paid   $ 2,000,000  
Payment term   3 years  
Payment commencement date   2018-08  
License maintenance fee $ 33,000 $ 10,000  
Total milestone payments   21,000,000  
Amounts due to agreement   0  
Sponsored Research Agreements | Penn      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Obligation to be paid   $ 12,483,000  
Number of faculty member | Faculty   2  
Funding term end date   2022-11  
Cost incurred   $ 9,930,000  
Research and development expense   2,840,000 2,995,000
Sponsored Research Agreements | Penn | Prepaid Expenses and Other Current Assets      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Advance payments   346,000 1,851,000
Sponsored Research Agreements | Penn | Accrued and Other Current Liabilities      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Obligation to be paid   36,000 217,000
Master Translational Research Services Agreement      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Research and development expense   1,933,000 2,474,000
Remaining research and development expense to be incurred   1,360,000  
Subscription and Technology Transfer Agreement      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Research and development expense   150,000 $ 0
Oxford Biomedica      
Collaborations, Licensing Agreements And Other Agreements [Line Items]      
Obligation to be paid   4,000,000  
Research and development expense   $ 1,100,000